spacer
The Healthcare Sales & Marketing Network celebrates 23 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  zidovudine 

 HSMN NewsFeed - 6 Oct 2014
Mylan Launches Generic Combivir
Biopharmaceuticals Generics HIV/AIDS Product Launch
 HSMN NewsFeed - 7 Feb 2011
FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 3 Sep 2010
Gilead Sciences Submits European Marketing Application for Once-Daily Single-Tablet Regimen of Truvada(R) and TMC278 for the Treatment of HIV Infection
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 16 Feb 2010
Centocor Ortho Biotech Products and Amgen Finalize ESA Risk Evaluation and Mitigation Strategy (REMS) With FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Oct 2009
FDA Advisory Committee Recommends Approval of Pfizer's Selzentry for Use in Patients Starting HIV Therapy for the First Time
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 1 Aug 2008
Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla(R) (Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg) in Twelve Countries
Biopharmaceuticals HIV/AIDS Distribution
 HSMN NewsFeed - 11 Mar 2008
Totality of Available Data Reaffirms PROCRIT(R) (Epoetin alfa) Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy-Induced Anemia
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Mar 2008
Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa)
Biopharmaceuticals
 HSMN NewsFeed - 21 Dec 2007
Medivir AB and Presidio Pharmaceuticals, Inc. Amend License Agreement.
Biopharmaceuticals HIV/AIDS Licensing
 HSMN NewsFeed - 11 Dec 2007
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 8 Nov 2007
Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 29 Oct 2007
Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 18 Oct 2007
European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 17 Oct 2007
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 11 Sep 2007
Ortho Biotech Supports FDA Advisory Committees' Recommendations on Use of ESAs in Chronic Renal Failure Patients
Biopharmaceuticals
 HSMN NewsFeed - 11 Sep 2007
Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
Biopharmaceuticals
 HSMN NewsFeed - 5 Sep 2007
Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
Biopharmaceuticals
 HSMN NewsFeed - 25 Jul 2007
Maraviroc Reduces HIV Viral Load in Treatment-Naive Patients, 48 Week Data Show
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 23 Jul 2007
144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 9 Mar 2007
Ortho Biotech Revises Prescribing Information for PROCRIT(R) (Epoetin alfa)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Dec 2006
96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 28 Sep 2006
New Data Reinforce Efficacy of TRIZIVIR(R) Alone in Treatment-Naive HIV Patients with Low Viral Load
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 14 Aug 2006
96-Week Data from Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination with Sustiva(R) Presented at XVI International AIDS Conference
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 12 Jul 2006
U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection
Biopharmaceuticals FDA HIV/AIDS
 HSMN NewsFeed - 8 Mar 2006
U.S. FDA Grants Traditional Approval for Gilead's Once-Daily HIV Medications Truvada(R) and Viread(R)
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 18 Jan 2006
Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of Combination HIV Therapy Published in New England Journal of Medicine
Biopharmaceuticals HIV/AIDS
Return to NewsFeed  

 Additional items found! 38

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 38 additional stories matching:
zidovudine
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.